АНТИГЕННЫЕ ПРЕПАРАТЫ

Изобретение относится к медицине и ветеринарии. Способы получения антигенных препаратов заключаются в том, что их получают из кератинофильных грибов рода Trichophiton или Microsporum или дрожжей рода Candida методами щелочного гидролиза. Полученные антигенные препараты могут быть использованы в качестве фармацевтических средств, в том числе вакцин, а также для лечения аллергии и модуляции иммунного ответа. 5 с. и 12 з.п.ф-лы, 4 ил., 12 табл.

МОДУЛЯЦИЯ СПЕЦИФИЧНОСТИ СТРУКТУРИРОВАННЫХ БЕЛКОВ

Изобретение относится к области биотехнологии, конкретно к пептидным лигандам человеческого плазматического калликреина, что может быть использовано в медицине. Путем скрининга библиотек мутантных пептидов получают лиганды к человеческому калликреину, библиотеки указанных лигандов и наборы библиотек указанных лигандов, отличающиеся тем, что полученный лиганд содержит аминокислотную последовательность WPAR. Изобретение позволяет получить лиганды к человеческому калликреину с повышенной специфичностью. 4 н. и 11 з.п. ф-лы, 16 ил., 22 табл., 6 пр.

КОМПОЗИЦИЯ И СПОСОБ ОБРАБОТКИ НЕОПЛАСТИЧЕСКОЙ КЛЕТКИ

Изобретение относится к медицине и касается иммунотоксина, обладающего неопластическим действием, композиции, обладающей неопластической активностью, содержащей иммунотоксин, и способа обработки неопластической клетки. Задача изобретения заключается в разработке способа селективного направления химиотерапевтического агента в клетке. Сущность изобретения состоит в том, что иммунотоксин, обладающий неопластическим действием, представляет собой конъюгат гелонина и моноклонального антитела, проявляющего специфичность связывания в отношении антигенного домена с - erb В-2 и представляющего собой Tab 250. Композиция, обладающая неопластической активностью, представляет собой иммунотоксин и фармацевтически приемлемый носитель. Способ обработки неопластической клетки включает введение эффективной дозы иммунотоксина в эту клетку. Технический результат заключается в усилении селективности доставки химиотерапевтического агента к клетке. 3 с. и 7 з.п. ф-лы, 7 ил.

ПРОДУКТ ПОЛИПЕПТИДНОЙ ПРИРОДЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ПРОТИВООПУХОЛЕВОЙ И АНАЛЬГЕЗИРУЮЩЕЙ АКТИВНОСТЬЮ

Соединения полипептидной природы, получаемые путем экстракции из гомогенатов тканей животных, которые могут индуцировать при введении разным видам животных, образование антител, способных узнавать in vivo или in vitro антигены, присутствующие в опухолевых клетках человека, и могут уменьшать или подавлять боль, вызывать эффект лизиса клеток и ингибировать или замедлять рост опухоли при введении людям, пораженным злокачественными опухолями разного типа. 3 с. и 9 з.п.ф-лы, 7 табл., 12 ил.

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА

... 1. Соединение (5,6-дигидро-4H-пирроло[3,2,1-ij]хинолин-1-ил)пиррол-2,5-диона, выбранное из группы, состоящей ...

МОДУЛЯЦИЯ СПЕЦИФИЧНОСТИ СТРУКТУРИРОВАННЫХ БЕЛКОВ

... 1. Пептидный лиганд, специфичный к человеческому калликреину, содержащий полипептид, включающий по меньшей мере три реакционноспособные группы, разделенные по меньшей мере двумя последовательностями петель, и молекулярный каркас, который образует ковалентные связи с указанными реакционноспособными группами полипептида таким образом, что по меньшей мере две полипептидных петли образуются на указанном молекулярном каркасе, где указанные петли указанного пептидного лиганда содержат три, четыре или пять, но менее шести, аминокислот.2. Пептидный лиганд по п. 1, где указанные петли пептидного лиганда содержат три аминокислоты, и указанный полипептид имеет консенсусную последовательность GFxxGRVxG, где Gпредставляет собой реакционноспособную группу.3. Пептидный лиганд по п. 2, который включает один из полипептидов4. Пептидный лиганд по п. 1, где указанные петли пептидного лиганда содержат пять аминокислот, и первая петля содержит консенсусную последовательность GGGxxNG, где Gпредставляет собой ...

КОМБИНАЦИЯ МОДУЛЯТОРА ИММУННЫХ КОНТРОЛЬНЫХ ТОЧЕК И КОМПЛЕКСА, СОДЕРЖАЩЕГО ПРОНИКАЮЩИЙ В КЛЕТКУ ПЕПТИД, КАРГО-МОЛЕКУЛУ И ПЕПТИДНЫЙ АГОНИСТ TLR, ДЛЯ ПРИМЕНЕНИЯ В МЕДИЦИНЕ

СТАБИЛИЗИРОВАННЫЕ ЖИДКИЕ ФЕРМЕНТНЫЕ КОМПОЗИЦИИ

... 1. Стабилизированная жидкая композиция, содержащая субтилизин и пептидный альдегид формулы B-B-B-Н, гдеН означает водород;Bпредставляет собой остаток Tyr;Bпредставляет собой один аминокислотный остаток Ala или Val; иBпредставляет собой один аминокислотный остаток с присоединенной бензилоксикарбонильной группой (Cbz), или Впредставляет собой два аминокислотных остатка, содержащих ацетильную (Ас) N-концевую защитную группу.2. Композиция по п. 1, где Bпредставляет собой один остаток Gly, Arg или Leu с присоединенной бензилоксикарбонильной (Cbz) группой.3. Композиция по п. 1, где Bсостоит из двух аминокислотных остатков, содержащих ацетильную (Ас) N-концевую защитную группу, где один из остатков Впредставляет собой Phe, Gly или Leu, а второй остаток Впредставляет собой Phe, Gly, Leu, Tyr или Trp.4. Стабилизированная жидкая композиция, содержащая субтилизин и пептидный альдегид формулы Z-RAY-H, Ac-GAY-H, Z-GAY-H, Z-RVY-H, Z-LVY-H, Ac-LGAY-H, Ac-FGAY-H, Ac-YGAY-H, Ac-FGVY-H или Ac-WLVY-H, где ...

BIOLOGISCH AKTIVE SUBSTANZ MIT IMMUNMODULIERENDEN EIGENSCHAFTEN, VERFAHREN ZU IHRER GEWINNUNG UND AUS IHR HERGESTELLTE, PHARMAZEUTISCHE ZUBEREITUNG

MODIFIZIERTE MRNA ZUSAMMENSETZUNGEN

Verfahren zum Herstellen eines Polypeptids von Interesse in einer Säugerzelle oder einem Säugergewebe, wobei das Verfahren ein Inkontaktbringen der Säugerzelle oder des Säugergewebes mit einer Formulierung umfasst, die eine modifizierte mRNA umfasst, die für das Polypeptid von Interesse codiert, wobei die Formulierung aus der Gruppe bestehend aus Nanopartikeln, Poly(milchsäure-co-glykolsäure)(PLGA)-Mikrosphären, Lipidoid, Lipoplex, Liposom, Polymeren, Kohlenhydraten (einschließlich einfacher Zucker), kationischen Lipiden, Fibringel, Fibrinhydrogel, Fibrinkleber, Fibrindichtmittel, Fibrinogen, Thrombin, schnell eliminierten Lipidnanopartikeln (reLNPs) und Kombinationen davon ausgewählt ist.

PRODUCT FOR STIMULATING THE SYNTHESIS OF MELANOTIC PIGMENT IN THE SKIN

Binding constructs and methods for use thereof.

PROCEDURES FOR THE REGULATION AND TREATMENT OF TUBERÖSE SKLEROSE COMPLEX ASSOCIATED ILLNESSES

BINDUNGSKONSTRUKTE AND PROCEDURE FOR THEIR USE

PROCEDURE FOR THE DETERMINATION UNKNOWN QUANTITIES OF A PNS SEQENZ AND ITS USES

MONOCLONAL ANTIBODIES AGAINST HUMAN IGE

ACTIVE HEDGEHOG PROTEIN KONJUGAT, PROCEDURE FOR THE PRODUCTION AND USE

PROCEDURE FOR THE STABILIZATION OF A HYDROPHOBIN CONTAINING SOLUTION AND FOR THE COATING OF A SURFACE WITH HYDROPHOBIN

BIOLOGICALLY ACTIVE SUBSTANCE iMMUNE-MODULATING PROPERTIES MIT, METHOD FOR THEIR pRODUCTION AND FROM YOUR MADE, PHARMACEUTICAL COMPOSITION

AGAINST C-ERB B-2 (HER-2/NEU) SURFACE ANTIGENS DIRECTION IMMUNTOXINE VEWANDTE

ANTIGENI PREPARATIONS

Novel methods of protein evolution

The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.

Modulation of antigen immunogenicity by addition of epitopes recognized by NKT cells

The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination.

Nutritive fragments, proteins and methods

Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.

Active hedgehog protein conjugate, process for its production and use

BRANCHED DEGRADABLE POLYETHYLENE GLYCOL BINDER

The present invention provides a biologically-related substance to which a branched degradable polyethylene glycol derivative being decomposed in cells and being represented by formula (A) below is bound. (In the formula, each symbol is as defined in the present specification.) ...

TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY

The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.

WALNUT OLIGOPEPTIDE POWDER, AND PREPARATION METHOD AND APPLICATION THEREOF

The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight of less than 1,500 Da. The method comprises extracting walnut proteins using a highly efficient countercurrent extraction process, and subjecting the extract to filtration, enzymolysis, purification with a microfiltration membrane and an ultrafiltration membrane, concentrating, and spray drying to obtain the oligopeptide powder. The oligopeptide powder has an anti-oxidant activity and provides a protective effect for a neuron, and thus can ameliorate or treat memory deterioration and relieve fatigue.

NOVEL COMPOUNDS

CELL CULTURE METHOD, CELL AGGREGATES, CELL AGGREGATION CONTROL AGENT, AND MEDIUM

ABSTRACT A method for culturing cells by which the diameter of cell aggregates can be controlled, and by which a large amount of cells can be obtained, a cell aggregate obtained by the method, a cell aggregation control agent, and a medium containing the cell aggregation control agent, are provided. A method for culturing cells by suspension culture, which method includes an aggregation control step of adding a substance that inhibits a cell adhesion molecule(s) of the cells to a medium to control cell aggregation of the cells, and the like are provided. CA 2974620 2021-01-12 ...

MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS

Abstract : It is provided a method and compound for the prevention of immune responses towards allofactors, and more specifically, a method to obtain an isolated peptide or a polypeptide with reduced capacity to activate NKT cells comprising the steps of : identification of at least one NKT cell epitope wherein the epitope comprises hydrophobic aminoacid residues in position P1 and/or P7 elimination of the epitope(s) by substituting hydrophobic aminoacid residues in position P1 and/or P7 with a non-hydrophobic residue. CA 2819182 2017-10-26 ...

NUTRITIVE FRAGMENTS, PROTEINS AND METHODS

Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.

TREATMENT OF ATONAL HOMOLOG 1 (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO ATOH1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.

ANTI-HUMAN IGE MONOCLONAL ANTIBODIES

Monoclonal antibodies specifically bind to human immunoglobulin E (IgE) and are characterized by the following properties. ? Molecular weight of approximately 150,000 determined by SDS-polyacrylamide gel electrophoresis (non-reduced state). ? Bind to human IgE-producing B cells. ? Recognize IgE bound to human or canine cell having Fc.epsilon. receptor. ? Antibodies having one of sequences No. 1 to 4 in the sequence list of N-terminal amino acid of L-chain. The antibodies bind specifically to IgE and are useful for the treatment of allergy and other medicines. 29 ...

CYCLODEXTRIN COMPOUNDS AND METHODS OF MAKING AND USE THEREOF

The present invention provides polyanionic, substituted CDs having cellular growth modulating activity. The invention further provides CDs having anionic groups on one side of the CD molecule. Therapeutic methods for using as well as methods of making the CD compounds of the invention are also disclosed herein.

NOVEL PEPTIDES DERIVED FROM HUMAN HEAT SHOCK PROTEIN 60 FOR TREATMENT OF DIABETES, COMPOSITIONS, METHODS AND KITS

Novel peptides which are epitopes of the human 60 kDa heat shock protein (hsp60) may be used for the diagnosis and treatment of insulin-dependent diabetes mellitus (IDDM). Pharmaceutical compositions containing such peptides and kits for use in diagnosis of IDDM are also disclosed.

METHOD FOR MANUFACTURING EXPANDED HEMATOPOIETIC CELLS WITH STEM CELL FACTOR POLYPEPTIDE

Novel stem cell factors, oligonucleotides encoding the same, and methods of production are disclosed. Pharmaceutical compositions and their use in manufacturing expanded hematopoietic cells are also disclosed.

Verfahren zur Darstellung von das Nebennierenrindenhormon enthaltenden Präparaten, die frei von 1-(3,4-Dioxyphenyl)-2-methylaminoäthanol-1 sind.

Procédé pour la préparation d'un produit apte à provoquer l'activation des pro-enzymes fibrinolytiques présents dans le sang

PROTEINS FOR TREATMENT OF DYSFUNCTIONS EPITHELIAL BARRIER

Inhibitors of MetAP2 and methods for treatment of obesity

Mutated fn antibody with removed effector functions

Biologically active agent, method for its obtaining, pharmaceutical preparation based on it and application process thereof

Inhibitors of MetAP2 and methods for treatment of obesity

METHOD OF PRODUCING GLATIRAMERA ACETATE

FAMILY OF AXMI-192 PESTICIDE GENES AND METHODS OF THEIR APPLICATION

Conjugates comprising self assembly peptide molecule and uses thereof

PROCESS FOR THE PREPARATION OF A POLYPEPTIDE FOR ITS PHARMACEUTICAL USE

Un proceso para la preparacion de un polipéptido a partir de los aminoácidos L-alanina, ácido L-glutámico, L-lisina, y L-tirosina que comprende usar el N-tiocarboxianhidrido de al menos un aminoácido como material de partida. Reivindicacion 13: Un polipéptido o una sal del mismo aceptable para su uso farmacéutico, caracterizado porque comprende L-alanina, L-tirosina, L-glutamato, y L-lisina, que se prepara de acuerdo a un proceso que comprende los pasos de: a) polimerizar L-alanina, L-tirosina opcionalmente protegida, L-glutamato protegido, y L-lisina protegida para obtener un polipéptido protegido; y b) desproteger el polipéptido protegido para obtener el polipéptido o sal del mismo aceptable para su uso farmacéutico; en donde al menos uno de L-alanina, L-tirosina opcionalmente protegida, L-glutamato protegido, y L-lisina protegida es un N-tiocarboxianhidrido como se muestra en la formula 1, R representa la cadena lateral de L-alanina, L-tirosina opcionalmente protegida, L-glutamato protegido ...

LIN28-MEDIATED CONTROL OF LET-7 BIOGENESIS

The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogenesis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3' terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provides compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.

THERAPY FOR TISSUE MEMBRANE INSUFFICIENCY

Disclosed are methods of therapy applicable to pathologies that involve loss of integrity of tissue and organ membranes that lead to abnormal permeation of proteinic and other agents and their elimination or penetration of other anatomical functions. Such deficiencies are associated directly or indirectly, for example, with inflammatory diseases, with diabetes and others. The therapeutic method involves administering to the membrane in need of treatment a therapeutic amount of an oligosaccharide, preferably a cyclic oligosaccharide, having up to about 10 sugar units per molecule and having at least 1.4 anionic substituents per sugar unit. The anionic substituents are preferably the residues of strong acids.

Melanocortin receptor ligands

The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

Antigen delivery vectors and constructs

The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

IMMUNOGENIC COMPOSITION AND USES THEREOF

The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.

S-Alkyl-Sulphenyl Protection Groups in Solid-Phase Synthesis

A novel method for on-resin formation of disulfide-borne cyclization of peptides is devised.

Predictive marker for topoisomerase I inhibitors

The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine the presence of phosphorylation of topoisomerase I polypeptide, in some embodiments phosphorylation at residue ...

Peptide-based multiple-drug delivery vehicle

A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.

UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА

Изобретение относится к новым пирролохинолинилпирролидин-2,5-дионам формулы IVa, IVb, Va или Vb или их фармацевтически приемлемым солям: ! ! ! где R1, R2, R3 и R4 независимо означает Н; Q означает бензоконденсированный 5-членный гетероарил с одним атомом N; Х означает -(СН2)-; Y означает -(СН2)-связи; m равно 1 или 2. Соединения ингибируют рост раковых клеток, что позволяет использовать их в фармацевтических композициях. 3 н. и 9 з.п. ф-лы, 3 табл., 12 ил.

ОРТОГОНАЛЬНЫЕ БЕЛКИ CAS9 ДЛЯ РНК-НАПРАВЛЯЕМОЙ РЕГУЛЯЦИИ И РЕДАКТИРОВАНИЯ ГЕНОВ

Изобретение относится к биотехнологии. Описаны способы для модулирования экспрессии целевой нуклеиновой кислоты в клетке, включающие применение множества ортогональных белков Cas9 для того, чтобы одновременно и независимо регулировать соответствующие гены или одновременно и независимо редактировать соответствующие гены. Изобретение расширяет арсенал средств, направленных на активирование экспрессии генов. 5 н. и 19 з.п. ф-лы, 17 ил., 1 табл., 20 пр.

ОРТОГОНАЛЬНЫЕ БЕЛКИ Cas9 ДЛЯ РНК-НАПРАВЛЯЕМОЙ РЕГУЛЯЦИИ И РЕДАКТИРОВАНИЯ ГЕНОВ

Изобретение относится к области биотехнологии, в частности к способу модулирования экспрессии двух или более целевых генов в эукариотической клетке, предусматривающему использование ортогональных РНК-направляемых не обладающих нуклеазной активностью ДНК-связывающих белков CRISPR-системы Типа II, которые связываются с двумя или более целевыми генами и направляются двумя или более направляющими РНК. Также раскрыты способы изменения одного или более целевых генов в эукариотической клетке, также предусматривающие использование ортогональных РНК-направляемых не обладающих нуклеазной активностью ДНК-связывающих белков CRISPR-системы Типа II. Изобретение также относится к эукариотической клетке, экспрессирующей гены, которые модулируются вышеуказанными способами. Изобретение позволяет эффективно модулировать экспрессию двух или более целевых генов в эукариотической клетке. 6 н. и 44 з.п. ф-лы, 17 ил., 1 табл., 20 пр.

СТАБИЛИЗИРОВАННЫЕ ЖИДКИЕ ФЕРМЕНТНЫЕ КОМПОЗИЦИИ

Изобретение относится к пептидным альдегидам с тирозином в качестве C-концевого остатка, которые являются особенно эффективными для стабилизации протеаз типа субтилизина в жидких моющих средствах. 3 н. и 3 з.п. ф-лы, 3 пр.

Способ получения полностью гидролизованного коллагена

Изобретение относится к способу получения высокоочищенной смеси из 15 свободных аминокислот, полученной путем полного гидролиза коллагена. Способ получения полностью гидролизованного коллагена включает гидролиз в присутствии соляной кислоты при температуре +120-125°C; сорбцию аминокислот коллагена на среднесшитом катионите, например КУ-2-8; элюцию аминокислот и аммиака 2Н щелочью; отгонку аммиака из элюата под вакуумом; нейтрализацию и осветление раствора аминокислот на ионосорбенте ИА-4, согласно изобретению часть соляной кислоты, химически не связанную с аминокислотами, после окончания гидролиза удаляют в виде хлористого водорода путем вакуум-отгонки, пары хлористого водорода и воды поглощают в замкнутом цикле холодной водой и полученную соляную кислоту используют в процессе гидролиза коллагена. Способ позволяет исключить стадию нейтрализации соляной кислоты на анионите типа АН-31 в ОН-форме с последующей его регенерацией раствором щелочи, сократить количество отечных вод. 1 пр.

СПОСОБ ОПРЕДЕЛЕНИЯ ПРОФИЛЯ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ ПЕПТИДОВ-АГОНИСТОВ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОТЕАЗАМИ, 1 ТИПА В ЭКСПЕРИМЕНТАЛЬНЫХ УСЛОВИЯХ, ИМИТИРУЮЩИХ ИШЕМИЧЕСКИЕ

Изобретение относится к области биохимии, а именно к способу определения профиля функциональной активности пептидов-аналогов N-концевого фрагмента рецепторов, активируемых протеазами 1 типа на основе зависимости их эффектов от активности β-аррестина-2. Способ включает определение профиля функциональной активности пептидов-аналогов N-концевого фрагмента рецепторов, активируемых протеазами 1 типа в экспериментальных условиях, имитирующих ишемические, in vitro и/или in vivo не менее чем на 4 экспериментальных группах, из которых формируют по меньшей мере две подгруппы, которые включают по меньшей мере группы 1 и 2 с нормальной активностью β-аррестина-2 и по меньшей мере группы 3 и 4 с подавленной активностью β-аррестина-2, при этом по меньшей мере группы 1 и 3 подвергают воздействию только ишемических условий, а группы 2 и 4 подвергают воздействию и ишемических условий, и тестируемого пептида, далее проводят определение профиля активности пептида путем сравнения степени тяжести ишемических ...

СВЯЗАННЫЕ С ДИПЕПТИДОМ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

... 1. Пролекарство, включающее структуру:A-B-Q;где Q представляет собой биоактивный пептид;где А-В включает структуру:где(I) Rи Rнезависимо выбирают из группы, состоящей из Н, C-Cалкила, C-Cалкенила, (C-Cалкил)ОН, (C-Cалкил)SH, (С-Салкил)SCH, (C-Cалкил)CONH, (C-Cалкил)СООН, (C-Cалкил)NH, (C-Cалкил)NHC(NH )NH, (С-Cалкил)(С-Сциклоалкила), (С-Салкил)(С-Сгетероциклического радикала), (С-Салкил)(С-Сарил)R, (C-Cалкил)(С-Сгетероарила) и C-Cалкил(W)C-Cалкила, где Wпредставляет собой гетероатом, выбираемый из группы, состоящей из N, S и О, или Rи Rвместе с атомами, к которым они присоединены, образуют С-Сциклоалкил;Rпредставляет собой C-Cалкил;каждый из Rи Rпредставляет собой Н;Rпредставляет собой NHR, или Rи Rвместе с атомами, к которым они присоединены, образуют 4-, 5- или 6-членное гетероциклическое кольцо;Rпредставляет собой Н или C-Cалкил; иRвыбирают из группы, состоящей из Н и ОН;причем А-В связан с Q через амидную связь между А-В и алифатической аминогруппой Q;причем полупериод химического отщепления ...

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА

... 1. Соединение пирролохинолинилпирролидин-2,5-диона формулы IVa, IVb, Va или Vb или его фармацевтически приемлемая соль: где R1, R2 и R3 независимо выбирают из группы, состоящей из водорода, F, Cl, Br, I, -NR5R6, -(C1-C6)алкила, замещенного -(C1-C6)алкила, -(C3-C9)циклоалкила, замещенного -(C3-C9)циклоалкила, -O-(C1-C6)алкила, замещенного -O-(C1-C6)алкила, -O-(C3-C9)циклоалкила и замещенного -O-(C3-C9)циклоалкила, арила, гетероарила, гетероциклила; R4 независимо выбирают из группы, состоящей из водорода, -(C1-C6)алкила, -CH2R7; R5, R6 независимо выбирают из группы, состоящей из водорода и -(C1-C6)алкила; R7 независимо выбирают из группы, состоящей из -O-P(=O)(OH)2, -O-P(=O)(-OH)(-O-(C1-C6)алкил), -O-P(=O)(-O-(C1-C6)алкил)2, -O-P(=O)(-OH)(-O-(CH2)-фенил), -O-P(=O)(-O-(CH2)-фенил)2, группы карбоновой кислоты, группы аминокарбоновой кислоты и пептида; Q выбирают из группы, состоящей из арила, гетероарила, -O-арила, -S-арила, -O-гетероарила и -S-гетероарила; X выбирают из группы, состоящей из ...

СТАБИЛИЗИРОВАННЫЕ ЖИДКИЕ ФЕРМЕНТНЫЕ КОМПОЗИЦИИ

... 1. Жидкая композиция, включающая субтилизин и пептидное соединение формулы B2-B1-B0-R, где ! R представляет собой водород, CH3, CX3, CHX2 или CH2X, где X представляет собой атом галогена; ! B0 представляет собой остаток фенилаланина с OH-заместителем в пара-положении и/или мета-положении; ! B1 представляет собой один аминокислотный остаток; и !B2 состоит из одного или более аминокислотных остатков, необязательно включающих N-концевую защитную группу. ! 2. Жидкая композиция по п.1, где B2 состоит из одного или двух аминокислотных остатков, включающих N-концевую защитную группу. ! 3. Жидкая композиция, включающая субтилизин и пептидное соединение формулы B2-B1-B0-R, где ! R представляет собой водород, CH3, CX3, CHX2 или CH2X, где X представляет собой атом галогена; ! B0 представляет собой один аминокислотный остаток; ! B1 представляет собой один аминокислотный остаток; и ! B2 представляет собой остаток Gly, Arg или Leu с присоединенной N-концевой защитной группой. ! 4. Жидкая композиция по ...

СИСТЕМЫ ТВЕРДОФАЗНОЙ ФЕРМЕНТАЦИИ И СПОСОБ ПРОИЗВОДСТВА ВЫСОКОКАЧЕСТВЕННОГО БЕЛКОВОГО КОНЦЕНТРАТА И ЛИПИДОВ

СОСТАВЫ НА ОСНОВЕ МОДИФИЦИРОВАННОГО НУКЛЕОЗИДА, НУКЛЕОТИДА И НУКЛЕИНОВОЙ КИСЛОТЫ

... 1. Фармацевтическая или диагностическая композиция, содержащая состав, содержащий модифицированную мРНК, кодирующую целевой полипептид.2. Фармацевтическая или диагностическая композиция по п. 1, где фармакологический эффект(a) больше, чем фармакологический эффект, связанный с терапевтическим агентом, который, как известно, вызывает указанный фармакологический эффект;(b) больше, чем фармакологический эффект, вызванный композицией, содержащей свободную модифицированную мРНК, кодирующую целевой полипептид;(c) больше, чем фармакологический эффект, вызванный композицией, содержащей немодифицированную мРНК, кодирующую целевой полипептид; или(d) приводит к терапевтически эффективному результату при заболевании, расстройстве, состоянии или инфекции, и предпочтительно выбран из группы, состоящей из изменения количества клеток, изменения химических реакций в сыворотке, изменения активности ферментов, повышения уровня гемоглобина и повышения уровня гематокрита.3. Способ получения целевого полипептида ...

ИЗМЕНЕНИЕ ИММУНОГЕННОСТИ АНТИГЕНА ПУТЕМ ВВЕДЕНИЯ ЭПИТОПОВ, УЗНАВАЕМЫХ NKT-КЛЕТКАМИ

... 1. Способ получения пептидов или полипептидов, содержащих искусственную последовательность, способную активировать NKT-клетки, указанный способ, включающий стадии:(a) установления пептидов или полипептидов, которые не активируют NKT-клетки;(b) введения, по меньшей мере, одного CD1d-связывающего мотива путем введения, замены и/или делеции аминокислоты.2. Способ по п.1, отличающийся тем, что CD1d-связывающий мотив представляет собой [FWHY]-XX-[ILMV]-XX-[FWHY].3. Способ по п.2, согласно которому указанные пептиды или полипептиды, которые не активируют NKT-клетки, содержат, по меньшей мере, один предполагаемый CD1d-связывающий мотив, выбранный из [FWHY]-R-[ILMV] и/или [ILMV]-R-[FWHY], где R представляет собой аминокислоту или аминокислотную последовательность.4. Способ по п.3, в котором указанный, по меньшей мере, один предполагаемый CD1d-связывающий мотив выбирают из аминокислотной последовательности [FWHY]-XX-[ILMV], [ILMV]-XX-[FWHY], [FWHY]-XXX-[ILMV], [ILMV]-XXX-[FWHY], [FWHY]-X-[ILMV], ...

Monoklonale Antikörper gegen humanes IgE

Improvements in drug delivery

VACCINES ON BASIS OF CHANGED BOVINER HERPESVIREN TYPE 1

THE MAC-1-BINDUNGSSTELLE OF ICAM-1

DISULFAT OF WS-7622A, PROCEDURE FOR THE PRODUCTION AND USE

MONOCLONAL ANTIBODY, the DIAPHRAGM PHOPHOLIPASE a2 RECOGNIZES AND IMMUNE TEST FOR DIAPHRAGM PHOSPHOLIPASE a2.

OF 60 PEPTIDE FOR THE TREATMENT OF DIABETES, APPROPRIATE COMPOSITIONS, DEDUCED BY HUMAN HEAT SHOCK PROTEIN, PROCEDURES AND KITS

IMPROVED EXTRAKTIONSVERFAHREN

MOLECULES WITH LONGER RADIOACTIVE HALF-LIVES, COMPOSITIONS AND THEIR USE

SPHÄROIDI PREPARATION

THERAPEUTIKA AND DIAGNOSTIKA, CELLULAR ACCESSIBILITY ON CYTOKINE ADJUSTING

IN THE HUMAN THERAPY USEFUL SUBSTANCES PEPTIDI NATURE.

HO-1 SUPPRESSOR AS DIAGNOSTIC AND PROGNOSTIC TEST FOR DEMENTIA DISEASES

MONOCLONAL ANTIBODY AGAINST A HUMAN MDR1 GENE PRODUCT, A RESISTANCE AGAINST DIFFERENT MEDICINES PRODUCES AND ITS USE

COMPOUNDS COMPRISING PSEUDO-AMINO ACIDS

Stem cell factor

Compositions and methods for identifying biologically active molecules

Melanocortin receptor ligands

Method and electronic system for predicting at least one fitness value of a protein, related computer program product

This method for predicting at least one fitness value of a protein is implemented on a computer and includes the following steps: encoding (100) the amino acid sequence of the protein into a numerical sequence according to a protein database, the numerical sequence comprising a value for each amino acid of the sequence; calculating (110) a protein spectrum according to the numerical sequence; and for each fitness: comparing (130) the calculated protein spectrum with protein spectrum values of a predetermined database, said database containing protein spectrum values for different values of said fitness, predicting (130) a value of said fitness according to the comparison step.

Orthogonal Cas9 proteins for RNA-guided gene regulation and editing

Methods of modulating expression of a target nucleic acid in a cell are provided including use of multiple orthogonal Cas9 proteins to simultaneously and independently regulate corresponding genes or simultaneously and independently edit corresponding genes.

MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY

FLUOROCARBON ANTIGEN DELIVERY VECTORS AND CONSTRUCTS

... ²²²The present invention relates to fluorocarbon vectors for the delivery of ²antigens to immunoresponsive target cells. It further relates to fluorocarbon ²vector-antigen constructs and the use of such vectors associated with antigens ²as vaccines and immunotherapeutics in animals.² ...

SYSTEM AND PROCESS FOR INCREASING PROTEIN PRODUCT YIELD FROM BACTERIAL CELLS

Protein-rich nutrient supplements and animal feed supplements derived from an anaerobic bacterial process are generated through a myriad of cell rupturing and protein fractionation/purification processes. Bacterial fermentation systems and methods of obtaining one or more protein-containing portions from a fermentation process using carbon monoxide-containing gaseous substrates increasing protein product yield from bacterial cells are provided. The invention further provides compositions of protein-rich nutrient supplements with useful applications for intake by a variety of different animals and humans.

MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

Recombinant fusion protein and polynucleotide construct for immunotoxin production

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

High affinity antibodies to human il-6 receptor

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K D of about 500 pM or less and blocks IL-6 activity with an IC 50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Plant diacylglycerol acyltransferases

This invention relates to an isolated nucleic acid fragment encoding a diacylglycerol acyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the diacylglycerol acyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the diacylglycerol acyltransferase in a transformed host cell.

Homogenous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

ANTI-Aß OLIGOMER HUMANIZED ANTIBODY

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Immunoglobulin variants with altered binding to protein a

Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.

Modified Fc Molecules

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Natriuretic activities

This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.

Il-1beta binding antibodies and fragments thereof

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Dna vaccine for alzheimer's disease

The present invention aims to provide a DNA vaccine for Alzheimer's disease. The present invention provides a recombinant vector which comprises DNA encoding amyloid β and DNA encoding a Th2 cytokine, as well as a DNA vaccine for Alzheimer's disease which comprises this vector.

Complement receptor 2 targeted complement modulators

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Methods and compositions for liver cancer therapy

The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Antibodies against fatty acid synthase

The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

METHODS FOR TREATING IgE-MEDIATED DISORDER

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins

The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention.

Recombinant Anti-VLA4 Antibody Molecules

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Hk1-binding proteins

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.

Immunological herpes simplex virus antigens and methods for use thereof

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Antibody gene transfer and recombinant aav therefor

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Posterior segment drug delivery

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Method of Administering an Antibody

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Cell lines producing blocking antibodies to human RANKL

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Polyacridine nucleic acid delivery peptide complexes

The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes.

Vaccine

The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.

Methods of treating pain

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-b-amyloid antibody

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Glioblastoma multiforme-reactive antibodies and methods of use thereof

The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.

RBM3 in Testicular Cancer Diagnostics and Prognostics

The present disclosure provides a method for determining whether a mammalian subject belongs to a first or a second group, wherein subjects of the first group have a higher risk of having a testicular disorder than subjects of the second group, comprising the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of an earlier obtained sample comprising biological material from a testicle of said subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. Further, a prognostic method for testicular cancer is provided, as well as means and uses with prognostic and diagnostic applications.

Method of detecting progression of a neurodementing disease

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Ucp4

The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.

Antibody fusion-mediated plant resistance against Oomycota

The present invention relates to fusion proteins comprising anti-Oomycotic proteins or peptides linked to an antibody or fragment thereof specifically recognising an epitope of an Oomycota. The invention is also directed to polynucleotides coding for the fusion proteins. The embodiments of the present invention are particularly useful for the protection of plants against Oomycota. The invention therefore comprises transgenic plants expressing the fusion proteins of the present invention.

Engineered anti-il-13 antibodies, compositions, methods and uses

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Human monoclonal antibodies to ctla-4

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

TREATMENT OF CELIAC DISEASE WITH IgA

A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

Crystal structure of glutaminyl cyclase

A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.

Compositions for targeting conducting airway cells comprising adeno-associated virus constructs

An artificial AAV capsid comprising a heterologous conducting airway targeting sequence is provided. The artificial AAV is useful as a targeting moiety, for delivery of heterologous molecules which are associated therewith. The artificial AAV is also useful in the generation of AAV vectors having the artificial capsid. Also described are methods of modifying the native tropism and transduction efficiency of vectors by improving and/or ablating their ability to transduce conducting airway cells. Methods of targeting conducting airway cells and delivering therapeutic and other molecules thereto are also provided.

ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Peripheral blood sparc binding antibodies and uses thereof

The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.

Methods of diagnosing cervical cancer

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Anti-vegf-c antibodies and methods using same

The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.

Method for temporally controlling the biological activity of proteins in vertebrates, and applications thereof

The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor α, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.

method for promoting bone growth using activin-actriia antagonists

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

Anti- integrin antibodies, compositions, methods and uses

The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Methods of Treating Neurological Disorders

The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Methods and compositions for modification of a hla locus

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Rtef-1 variants and uses thereof

Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.

Method for Treating Psoriatic Arthritis by Administering an Anti-IL-12 Antibody

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.

Psca: prostate stem cell antigen and uses thereof

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Monoclonal Antibodies to Hepatocyte Growth Factor

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Il-17 homologous polypeptides and therapeutic uses thereof

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Aminoacyl trna synthetases for modulating hematopoiesis

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.

Therapeutic use of anti-cs1 antibodies

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Novel Target for Regulating Multiple Sclerosis

Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.

Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates

We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.

Use of e. coli surface antigen 3 sequences for the export of heterologous antigens

The present invention provides an export signal system based on E. coli CS3 antigen for directing the secretion of foreign antigens from host cells. In particular, the invention describes genetic constructs encoding fusion proteins that contain a CS3 export signal fused to at least one heterologous amino acid sequence. Attenuated microorganisms expressing the fusion proteins and pharmaceutical compositions comprising such attenuated microorganisms are also disclosed.

Tetravalent influenza vaccine and use thereof

Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second, third and fourth nucleic acid sequences each encode an influenza HA with a different amino acid sequence. Also provided are recombinant baculoviruses displaying a first, second, third and fourth influenza virus HA fusion protein in the baculovirus envelope, wherein each HA fusion protein comprises a different HA amino acid sequence. Tetravalent influenza virus vaccines comprising the recombinant baculoviruses disclosed herein are further provided. In addition, methods of immunizing a subject against influenza virus using the tetravalent influenza virus vaccines are provided. In particular examples of the compositions and methods disclosed herein, the HA polypeptides are from H5N1 influenza virus.

assay for detecting vitamin d and antibodies therefor

A molecule which recognises holo-DBP but which does not recognise apo-DBP or has relatively low affinity thereto.

Mir-21 promoter driven targeted cancer therapy

The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.

Dual targeting antibody of novel form, and use thereof

The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.

Test agent for visceral obesity and use thereof

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

Treatment of vascularized pigment epithelial detachment with anti-vegf therapy

Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed.

Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Methods of treating inflammation

A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.

Compositions and methods for identifying enzyme and transport protein inhibitors

The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Prevention and treatment of blood coagulation-related disases

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Antagonists of pcsk9

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Human cytomegalovirus neutralising antibodies and use thereof

The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.

Antibodies to troponin i and methods of use thereof

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof

Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.

Antagonists of pcsk9

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Soluble il-17ra/rc fusion proteins and related methods

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Cd33 binding agents

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

Methods for preventing and treating angioedema

One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.

Antagonists of pcsk9

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Myostatin binding agents

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

Therapeutics for age-related macular degeneration

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Therapeutic and diagnostic anti-hsp70 antibodies

Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.

Immunocompromised Ungulates

Porcine animals, tissue and organs as well as cells and cell lines derived from such animals are provided that lack functional endogenous immunoglobulin loci and are deficient in immunoglobulin expression and B-cells. These animals are useful as model systems for research and for development of new pharmaceutical and biological agents. In addition, methods are provided to prepare such animals.

Process for producing poxviruses and poxvirus compositions

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.

Recombinantly modified plasmin

Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme

Anti-vegf-d antibodies

The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D.

Tat-Based Tolerogen Compositions and Methods for Making and Using Same

A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Hcv vaccines and methods for using the same

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Nucleotide repeat expansion-associated polypeptides and uses thereof

Isolated polypeptides that are endogenously expressed from nucleotide repeat expansions are disclosed. In some cases, the polypeptides include polypeptide repeats. In some cases, the polypeptide repeats include at least five contiguous repeats of a single amino acid. In other cases, the repeats include at least six contiguous amino acids of a tetra- or penta-amino acid repeat block.

Mice That Make VL Binding Proteins

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.

Humanized antibodies against light and uses thereof

The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).

Use of anti-cd20 antibody for treating primary intraocular lymphoma

An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains originate from a non-murine species, said antibody being used for treating primary intraocular lymphoma.

CD86 Antagonist Multi-Target Binding Proteins

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Anti-ferroportin 1 monoclonal antibodies and uses thereof

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

Anti-human cd52 immunoglobulins

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Antibodies having altered effector function and methods for making the same

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Phospholipases, nucleic acids encoding them and methods for making and using them

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

Inhibition of secretion from non-neuronal cells

The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.